Also found in: Dictionary.


trademark for a preparation of leuprolide, an antineoplastic agent.

leuprolide acetate (leuprorelin (UK))

Eligard, Lupron, Lupron Depot, Lupron Depot-Ped, Lupron Depot-3 Month, Lupron Depot-4 Month, Lupron-3 Month SR Depot, Prostap (UK)

Pharmacologic class: Gonadotropin-releasing hormone (GnRH) analog

Therapeutic class: Antineoplastic

Pregnancy risk category X


Inhibits and desensitizes GnRH receptors, thus inhibiting gonadotropin secretion when given continuously. This inhibition causes initial increase and then profound decrease in luteinizing hormone and follicle-stimulating hormone levels and, ultimately, reduces testosterone and estrogen sex hormones.


Eligard Depot: 7.5 mg, 22.5 mg, 30 mg, 45 mg

Injection: 1 mg/0.2 ml

Lupron Depot injection: 3.75 mg/ml, 7.5 mg/ml

Lupron Depot-3 month injection: 11.25 mg, 22.5 mg

Lupron Depot-4 month injection: 30 mg

Lupron Depot-Ped injection: 7.5 mg, 11.25 mg, 15 mg

Indications and dosages

Advanced prostate cancer

Adults: 1 mg subcutaneously daily (1 mg/0.2-ml formulation). For Lupron Depot formulation, 7.5 mg I.M. monthly, 22.5 mg I.M. q 3 months, or 30 mg I.M. q 4 months. For Eligard formulation, 7.5 mg subcutaneously monthly, 22.5 mg subcutaneously q 3 months, 30 mg subcutaneously q 4 months, or 45 mg subcutaneously q 6 months.


Adults: 3.75 mg I.M. (depot injection) as a single injection once monthly, or 11.25 mg I.M. q 3 months. Duration is up to 6 months.

Adjunct to iron therapy in anemia caused by uterine leiomyomas

Adults: 3.75 mg I.M. monthly or 11.25 mg I.M. q 3 months as a single dose. Recommended duration is 6 months or less.

Central precocious puberty

Children: 50 mcg/kg/day subcutaneously as a single injection, increased in increments of 10 mcg/kg/day as needed

Children weighing more than 37.5 kg (82.5 lb): Initially, 15 mg of Depot-Ped I.M. q 4 weeks, increased in increments of 3.75 mg q 4 weeks as needed

Children weighing 25 to 37.5 kg (55 to 82.5 lb): Initially, 11.25 mg of Depot-Ped I.M. q 4 weeks, increased in increments of 3.75 mg q 4 weeks as needed

Children weighing less than 25 kg (55 lb): Initially, 7.5 mg of Depot-Ped I.M. q 4 weeks, increased in increments of 3.75 mg q 4 weeks as needed


• Hypersensitivity to drug, its components, GnRH, or other GnRH analogs
• Undiagnosed abnormal vaginal bleeding
• Pregnancy or breastfeeding


Use cautiously in:
• renal, hepatic, or cardiac impairment.


• Give Eligard within 30 minutes of mixing. After this time, discard.
• Administer Lupron injection immediately after mixing. Otherwise, discard.
• Administer Lupron Depot-Ped only under prescriber's supervision.

Adverse reactions

CNS: anxiety, depression, dizziness, drowsiness, asthenia, fatigue, headache, vertigo, syncope, mood changes

CV: palpitations, angina, arrhythmias, myocardial infarction

EENT: blurred vision

GI: nausea, vomiting, diarrhea, constipation, abdominal pain, dyspepsia, anorexia

GU: urinary frequency, hematuria, decreased testes size, erectile dysfunction, decreased libido, gynecomastia

Hematologic: anemia, thrombocytopenia

Respiratory: dyspnea, pleural rub, worsening of pulmonary fibrosis, pulmonary embolism

Skin: alopecia, pruritus, rash, diaphoresis

Other: sour taste, edema, hot flashes, anaphylaxis


Drug-diagnostic tests.Blood urea nitrogen, creatinine: increased levels

Pituitary-gonadal system tests: misleading results during and for up to 3 months after therapy

Patient monitoring

• Observe injection site for local reactions.

Monitor cardiovascular and respiratory status carefully to detect serious adverse reactions.
• Evaluate neurologic status. Institute safety measures as needed to prevent injury.
• Periodically monitor serum testosterone and prostate-specific antigen levels.

Patient teaching

• Inform patient that localized reaction may occur at injection site. Tell him to contact prescriber if symptoms don't resolve.
• Advise patient and family to watch for and report signs or symptoms of depression.
• Tell patient drug may cause libido changes or erectile dysfunction. Encourage him to discuss these problems with prescriber.
• Teach patient to minimize GI upset by eating small, frequent servings of food and drinking plenty of fluids.

Instruct female of childbearing age to use reliable contraception during therapy. Tell her to stop drug immediately and contact prescriber if she suspects pregnancy.

Tell female patient not to breastfeed.
• Caution patient to avoid driving and other hazardous activities until he knows how drug affects concentration and alertness.
• As appropriate, review all other significant and life-threatening adverse reactions and interactions, especially those related to the tests mentioned above.


A trademark for the drug leuprolide acetate.


a trademark for a parenteral antineoplastic drug (leuprolide acetate).


Oncology A depot leuprolide, a GnRH–gonadotropin releasing hormone, for palliating advanced prostate CA. See Prostate CA.
References in periodicals archive ?
Patient information 2 Patient 1 2 Casodex 11/12/15 3/13/15 3/13/15 Lupron (1 month) 11/6/15 6/29/15 12/5/15 9/5/15 After Lupron 10 days 14 days priapism stopped Lurpon ran out, 4 weeks (single 6 weeks priapism returned occurrence) Complications No Penile pain, pan management Libido on Lupron Slight decline Lost to followup Erections on Lupron Present Lost to followup Patient 3 4 Casodex No 8/28/15 8/28/15 9/25/15 Lupron (1 month) No 10/30/15 1/4/16 2/26/16 3/25/16 After Lupron N/A 10 days priapism stopped 21 days Lurpon ran out, N/A 6 weeks priapism returned Complications No No Lost job Libido on Lupron N/A Normal Erections on Lupron N/A Present P33.
Lupron is followed by injections that stimulate egg production.
Twice a day I inject myself subcutaneously, in the fat of the abdomen, with Lupron.
Abbott's and Takeda's Lupron Depot is a subcutaneously- or intramuscularly-delivered GnRH analogue used to treat advanced androgen-dependent prostate cancers.
The company said the percentage of treatment-compliant subjects receiving 1,500 mg of GTx-758 who achieved target testosterone was comparable to rates seen with treatments like Lupron.
Shih recommended Lupron injections to shrink the fibroids.
and leuprolide acetate, sold as Lupron, Eligard, Viadur and as generics.
The FDA approved bad drugs like Vioxx and Lupron, which cost tens of thousands of lives, but 90 studies showing that vitamin D from sunshine reduces cancer risk by 50% have been suppressed.
But there's an even more important reason for early acceptance of eventual transition: If clinicians believe early enough that your child is going to transition sex eventually, then they might use Lupron, a drug that reduces production of estrogen in females and testosterone in males, to delay onset of natural puberty.
Lupron is a Gonadotropin-Releasing Hormone Analog Agonist (GnRH); these drugs shut down the pituitary gland, thereby reducing the amount of testosterone produced by men, and estrogen produced by women: For women, this causes the rapid and artificial onset of menopause potentially with incapacitating and long-lasting effects.
To give us time, I was put on a regimen of Lupron shots every three months.
One drug commonly used, Lupron, has not been approved for this purpose, but rather is used 'off-label.